Bacterias for Energy: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
 
(6 intermediate revisions by the same user not shown)
Line 35: Line 35:


=A brief look at IP development at NanoLogix (formerly known as Infectech)=
=A brief look at IP development at NanoLogix (formerly known as Infectech)=
2005 Name change information: [[http://www.redorbit.com/news/health/141833/infectech_inc_approves_name_change_to_nanologix_and_enters_hydrogen/index.html]]


'''Output:'''<br>
'''Output:'''<br>
Line 43: Line 45:
''Data''
''Data''
*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee.  Revenue has started from this arrangement." http://www.tecnica.com/
*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee.  Revenue has started from this arrangement." http://www.tecnica.com/
**Nutra Pharma Corp is a biotechnology intellectual property holding company
**Nutra Pharma Corp is a biotechnology intellectual property holding company [[http://www.nutrapharma.com/]]
*Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for **Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
***"a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases" http://www.nutrapharma.com/
***"Nutra Pharma Corp. (OTCBB: NPHC) announced today that it has signed a letter of intent to acquire 100 percent of the capital stock of Infectech Inc.(Pink Sheets: IFEC) in a cash and stock transaction. The acquisition adds a complete line of patented and patent-pending products and applications." http://findarticles.com/p/articles/mi_m0EIN/is_2003_Sept_8/ai_107398671/
***Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for **Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)
*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)


Line 52: Line 56:
**the board is used "to help evaluate and target research and development efforts for products"
**the board is used "to help evaluate and target research and development efforts for products"
**http://www.reuters.com/article/pressRelease/idUS139804+11-May-2009+PRN20090511
**http://www.reuters.com/article/pressRelease/idUS139804+11-May-2009+PRN20090511
''Narrative''
*Third Party Verification of Findings "Dr. Paul Hyman of Ohio State University. Dr. Hyman has achieved the identification and bacterial genetic amplification of an important strain of Mycobacteria faster than what is presently in the medical literature." http://www.aegis.com/NEWS/BW/2004/BW040902.html
**Infectech has developed a diagnostic test kit based on this technology
''Tools''
''Tools''
*"NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts
*"NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts

Latest revision as of 14:03, 17 August 2009

The issue

Brief Outline of Research Results

Bacteria for Energy

A brief look at IP development at NanoLogix (formerly known as Infectech)

2005 Name change information: [[1]]

Output:
Tools

  • commercialization of technologies including:
    • the production of bacteria
    • disease testing kits

Data

  • "NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/
    • Nutra Pharma Corp is a biotechnology intellectual property holding company [[2]]
      • "a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases" http://www.nutrapharma.com/
      • "Nutra Pharma Corp. (OTCBB: NPHC) announced today that it has signed a letter of intent to acquire 100 percent of the capital stock of Infectech Inc.(Pink Sheets: IFEC) in a cash and stock transaction. The acquisition adds a complete line of patented and patent-pending products and applications." http://findarticles.com/p/articles/mi_m0EIN/is_2003_Sept_8/ai_107398671/
      • Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for **Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
  • "NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)

Input:
Data

Narrative

  • Third Party Verification of Findings "Dr. Paul Hyman of Ohio State University. Dr. Hyman has achieved the identification and bacterial genetic amplification of an important strain of Mycobacteria faster than what is presently in the medical literature." http://www.aegis.com/NEWS/BW/2004/BW040902.html
    • Infectech has developed a diagnostic test kit based on this technology

Tools

  • "NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts

Important Similar Research

NanoLogix Patent Policy

  • "NanoLogix intends to dominate the patent coverage for a variety of disruptive technologies at a time when the energy and healthcare industries are screaming for change," said David McClelland, President of NanoLogix. "We are seeing confirmation of this by the caliber of companies we are in discussions with who have expressed interest in our technology, in addition to significant progress we are making in our research collaborations," he added." http://www.azonano.com/news.asp?newsID=1006
  • Key Patents (?)
    • United States Patent 7,524,623, April 28, 2009 Method and device for rapid detection of microorganisms by changing the shape of micro-colonies
      • Abstract: "This invention describes a method of rapid detection of micro-colonies of microorganisms by changing their shape from a regular semi-sphere to a long and thin cylinder. Cells are trapped by filtration in long (diameter/length=1/10-1/100), cylindrical, parallel, micro-channels that are open from both sides, and attached to a filter from one side. A micro-channel plate houses a multiplicity of micro-channels (diameter of each channel=1 -20 .mu.m, and length 100-1000 .mu.m). The micro-channel plate with cells trapped on the surface of the filter is attached to a nutrient media agar block. Cells produce micro-colonies of a long and thin shape according the shape of the micro-channel. The growth of microorganisms in the micro-channels permits a change in the number of cells to accomplish light absorbance. Fewer cells need a shorter time to reproduce. Thus detection and counting of cells can be accomplished in a rapid fashion. The light absorbance can be enhanced by additional coloration of micro-colonies by cell dyes or artificial chromogenic or fluorogenic substrates."
    • United States Patent 7,473,552 January 6, 2009 Production of hydrogen gas and isolation of hydrogen producing microorganisms using replenishing coated substrates
      • Abstract: "The present invention provides a system of baiting and growing microorganisms on a gelatinous matrix. A bioreactor is provided wherein the bioreactor provides an environment conducive to the breakdown of organic aqueous material and the production of hydrogen from microorganisms and restrictive to the production of methane from methanogens. The bioreactor includes substrates coated with a gelatinous matrix, wherein the gelatinous matrix coating is replenished by additional coating material pumped into interior channels of the substrates wherein the substrates are permeable by the coating."

Bibliography

Navigation=

Back to Biotechnology_-_Genomic_and_Proteomics